AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Sep 13, 2022--
On Wednesday morning, September 14 th, two dozen advocates from AIDS Healthcare Foundation (AHF), the largest global AIDS organization, and its affiliates, Iris House and ACQC (AIDS Center of Queens County) will spearhead a protest targeting Gilead Sciences (GILD) during the annual Baird Global Healthcare Investor Conference being held at the Intercontinental – New York Barclay (111 E 48 th St) in New York City.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913006276/en/
Since the third quarter of 2020—less than two years—Gilead has also more than doubled the cost of its HIV/AIDS medication, Descovy, for the 340B program from $445.11 in 2020 to $987.55 in the second quarter of 2022. (Graphic: Business Wire)
Gilead officials will be presenting at the conference and the advocates will protest Gilead—“Greediad”—over the drug company’s latest, and illegal move to undermine safety net providers’ access to 340B program benefits. 340B is a drug-company-funded, government administered program that costs taxpayers nothing, and, according to HRSA “… enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”
WHAT: | AIDS Drug PricingPROTEST targeting Gilead Sciences, Inc. during the annual Baird Global Healthcare Investor Conference | |
|
| |
WHEN: | Wednesday, September 14 th —9:40AM – 10:15AM (approx.) | |
|
| |
WHERE: | InterContinental – New York Barclay | |
| 111 E. 48 th Street (between Park & Lexington Aves.), New York, NY 10017 | |
|
| |
WHO: | 20+ AIDS drug pricing protesters with “Greediad” and “Stop Being Greedy” signs | |
On-site AHF CONTACT: | Rasheed Gonga, (201) 241-0927 cell Rasheed.gonga@ahf.org |
In March of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs. Lawyers for the Health and Human Services Department (HHS) in both the Biden and Trump administrations have said these restrictions are clearly illegal, yet drug companies like Gilead forge ahead with the lawbreaking in search of even greater profits.
Since the third quarter of 2020—less than two years—Gilead has also more than doubled the cost of its HIV/AIDS medication, Descovy, for the 340B program from $445.11 in 2020 to $987.55 in the second quarter of 2022.
In response to Gilead’s (and others’) illegal restrictions on 340B access and its bald-faced greed for higher profits, AHF also asked Congress and the FDA to conduct a formal investigation of Gilead as well as increase scrutiny of the actions of pharmaceutical companies.
AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.6 million individuals in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth, follow us @aidshealthcare or subscribe to our AHF podcast “AHFter Hours.”
View source version on businesswire.com:https://www.businesswire.com/news/home/20220913006276/en/
CONTACT: Rasheed Gonga
Advocacy, Legislative Affairs & Community Engagement for AHF
+1.201.241.0927 mobile
Rasheed.gonga@ahf.orgImara Canady
National Director, Communications & Community Engagement for AHF
+1.770.940.6555 mobile
imara.canady@ahf.org
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: INFECTIOUS DISEASES ADVOCACY GROUP OPINION CONGRESSIONAL NEWS/VIEWS PUBLIC POLICY/GOVERNMENT HEALTHCARE REFORM PHILANTHROPY AIDS PHARMACEUTICAL HEALTH FOUNDATION
SOURCE: AIDS Healthcare Foundation
Copyright Business Wire 2022.
